{"classification":[{"coding":[{"code":"B01A","system":"http://www.whocc.no/atc/example"}]}],"combinedPharmaceuticalDoseForm":{"coding":[{"code":"tablet","system":"http://example.org.uk/fhir/dosefom"}]},"crossReference":[{"product":{"reference":{"reference":"MedicinalProductDefinition/genericEquilidonium"}}}],"id":"equilidem-basics","identifier":[{"system":"http://example.org.uk/fhir/product","value":"Equilidem25"}],"indication":"Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.","ingredient":[{"text":"Equilidonium Phosphate"},{"text":"Calcium Carbonate"}],"legalStatusOfSupply":{"coding":[{"code":"POM","display":"Prescription only medicine","system":"http://example.org.uk/fhir/legalstatusofsupply"}]},"name":[{"productName":"Equilidem 2.5 mg film-coated tablets"}],"operation":[{"organization":[{"display":"EquiliDrugCo Inc."}]}],"resourceType":"MedicinalProductDefinition","text":{"div":"
\n\t\t\t

\n\t\t\t\t\n\t\t\t\t\tGenerated Narrative\n\t\t\t\t\n\t\t\t

\n\t\t\t

\n\t\t\t\t\n\t\t\t\t\tId\n\t\t\t\t\n\t\t\t\t: equilidem-basics\n\t\t\t

\n\t\t\t

\n\t\t\t\t\n\t\t\t\t\tIdentifier\n\t\t\t\t\n\t\t\t\t: Equilidem25\n\t\t\t

\n\t\t\t

\n\t\t\t\t\n\t\t\t\t\tCombined Pharmaceutical Dose Form\n\t\t\t\t\n\t\t\t\t:\n\t\t\t\t\n\t\t\t\t\ttablet\n\t\t\t\t\n\t\t\t

\n\t\t\t

\n\t\t\t\t\n\t\t\t\t\tIndication\n\t\t\t\t\n\t\t\t\t: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\n\t\t\t

\n\t\t\t

\n\t\t\t\t\n\t\t\t\t\tLegal Status Of Supply\n\t\t\t\t\n\t\t\t\t:\n\t\t\t\t\n\t\t\t\t\tPrescription only medicine\n\t\t\t\t\n\t\t\t

\n\t\t\t

\n\t\t\t\t\n\t\t\t\t\tClassification\n\t\t\t\t\n\t\t\t\t:\n\t\t\t\t\n\t\t\t\t\tATC: B01A\n\t\t\t\t\n\t\t\t

\n\t\t\t

\n\t\t\t\t\n\t\t\t\t\tIngredient\n\t\t\t\t\n\t\t\t\t:\n\t\t\t

\n\t\t\t\n\t\t\t

\n\t\t\t\tNames\n\t\t\t

\n\t\t\t\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\t
\n\t\t\t\t\t\t-\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tProduct Name\n\t\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t*\n\t\t\t\t\t\n\t\t\t\t\t\tEquilidem 2.5 mg film-coated tablets\n\t\t\t\t\t
\n\t\t\t

\n\t\t\t\tCross References\n\t\t\t

\n\t\t\t\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\t
\n\t\t\t\t\t\t-\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tProduct\n\t\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t*\n\t\t\t\t\t\n\t\t\t\t\t\tLink to generic equivalent\n\t\t\t\t\t
\n\t\t\t

\n\t\t\t\tManufacturing/Business Operations\n\t\t\t

\n\t\t\t\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\t
\n\t\t\t\t\t\t-\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tManufacturer\n\t\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\t*\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tEquiliDrugCo Inc.\n\t\t\t\t\t\t\n\t\t\t\t\t
\n\t\t
","status":"generated"}}